While most pharmacy directors (54%) currently plan to manage all of their HDs using the containment properties and work practices listed in USP <800>, an increasing number are committing to performing risk assessments for certain HDs in order to handle these products using alternative containment strategies and/or work practices. As facilities continue to focus on their compliance efforts, it is expected that additional facilities will undertake risk assessments for certain HDs, such as oxytocin.

Compliant SOP development is underway to address HD handling in most facilities, with the largest facilities having made the most progress in this endeavor to date. Among the smallest facilities, 79% have created HD handling SOPs; that number jumps to 92% for facilities with 400+ beds.